The company is one step closer to securing an OK for its new cholesterol-busting drug.
News & Analysis: Esperion Therapeutics
The developer of a new cholesterol-lowering treatment is on a path toward commercialization.
The Super Bowl of biotech kicked off early for these companies.
Even in a surging market, these stocks fell. Find out why.
The company's making big strides toward winning approval of its first commercial medicine.
It could be the perfect time to consider adding these top healthcare stocks to your portfolio.
Highly anticipated trial results expected soon could move all three of these drugmakers.
The recent safety scare might not be as bad as feared. Does that make the highly-focused biotech stock a buy now?
Bargain hunters willing to accept big risks are pushing shares back up.
This Clinical-Stage Biotech's Tackling a Huge Health Issue, but It Has to Overcome Pessimistic Investors First
If this company has its way, then heart disease may soon have a new enemy.